$0.74
+0.04 (+5.89%)
Open$0.74
Previous Close$0.70
Day High$0.80
Day Low$0.70
52W High$31.42
52W Low$16.93
Volume—
Avg Volume691.0K
Market Cap7.51M
P/E Ratio—
EPS$0.15
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+3,641.2% upside
Current
$0.74
$0.74
Target
$27.73
$27.73
$20.43
$27.73 avg
$35.07
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.57M | 1.60M | 1.25M |
| Net Income | 4.2K | 5.8K | 3.4K |
| Profit Margin | 0.3% | 0.4% | 0.3% |
| EBITDA | 8.2K | 8.5K | 6.5K |
| Free Cash Flow | 4.7K | 4.2K | 2.8K |
| Rev Growth | -8.5% | +15.0% | -6.0% |
| Debt/Equity | 0.92 | 0.88 | 0.96 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |